CJC-1295 with DAC is a modified growth hormone-releasing hormone (GHRH) analog designed for extended activity in research settings. The addition of Drug Affinity Complex (DAC) allows for prolonged half-life and sustained signaling, supporting long-acting peptide research models.
This peptide is frequently studied in laboratory environments investigating growth hormone release patterns, IGF-1 signaling, and endocrine system regulation.
 
Mechanism of Action
 
CJC-1295 with DAC functions as a GHRH analog, interacting with receptors involved in growth hormone regulation.
 
Research has explored associations with:
 
• Increased growth hormone (GH) release
• Elevated IGF-1 signaling activity
• Support for physiologic, pulsatile hormone release patterns
• Extended activity due to albumin-binding properties of DAC
 
Due to DAC modification, this peptide may require additional time and/or slightly increased solvent volume during reconstitution to achieve full dissolution. Gentle mixing is recommended to ensure complete solubility.
 
Research Applications
 
CJC-1295 with DAC is commonly studied in laboratory settings involving:
• Growth hormone and IGF-1 pathway research
• Endocrine system signaling studies
• Metabolic regulation models
• Long-acting peptide and delivery system research
 
Product Specifications
 
• Peptide Content: 10mg Lyophilized Peptide
• Type: GHRH Analog with DAC
• Purity: ≥98% verified by HPLC testing
• Form: Lyophilized peptide powder
• Storage: Store lyophilized peptide frozen. After reconstitution, maintain refrigerated conditions (2–8°C) and avoid repeated freeze-thaw cycles.
 
Research Use Notice
 
This product is intended strictly for laboratory research and analytical purposes only.
 
• Not for human consumption
• Not for veterinary use
• Not intended for ingestion, injection, or bodily administration
• Not a drug, food, cosmetic, or dietary supplement
 
All information provided is for educational and scientific reference purposes only.